MedPath

CARBIDOPA

Carbidopa Tablets

Approved
Approval ID

83012ccc-aba2-45bb-9326-dc30cdeb4e3b

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Oct 13, 2022

Manufacturers
FDA

Zydus Lifesciences Limited

DUNS: 918596198

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

CARBIDOPA

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code70771-1355
Application NumberANDA209910
Product Classification
M
Marketing Category
C73584
G
Generic Name
CARBIDOPA
Product Specifications
Route of AdministrationORAL
Effective DateOctober 13, 2022
FDA Product Classification

INGREDIENTS (8)

CELLULOSE, MICROCRYSTALLINEInactive
Code: OP1R32D61U
Classification: IACT
FERRIC OXIDE YELLOWInactive
Code: EX438O2MRT
Classification: IACT
CARBIDOPAActive
Quantity: 25 mg in 1 1
Code: MNX7R8C5VO
Classification: ACTIM
CROSPOVIDONEInactive
Code: 2S7830E561
Classification: IACT
FERRIC OXIDE REDInactive
Code: 1K09F3G675
Classification: IACT
HYDROXYPROPYL CELLULOSE (1600000 WAMW)Inactive
Code: RFW2ET671P
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
MANNITOLInactive
Code: 3OWL53L36A
Classification: IACT

Drug Labeling Information

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LOINC: 51945-4Updated: 5/25/2018

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 70771-1355-1

Carbidopa Tablets

Rx only

100 Tablets

Carbidopa Tablets, 25 mg

SPL UNCLASSIFIED SECTION

LOINC: 42229-5Updated: 7/29/2020

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

CARBIDOPA - FDA Drug Approval Details